Books FDA Pharmaceutical Companies 
STAT
SEPTEMBER 14, 2023
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers. Continue to STAT+ to read the full story…
The FDA Law Blog
MARCH 18, 2025
Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product. FDA has already been there , of course, with respect to 180-day exclusivity.)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 25, 2023
Gregory’s industrial career spans an employment history with several major pharmaceutical companies. IPQ International Pharmaceutical Quality. He obtained his BS in Chemistry from St Xavier College, MS in Analytical Chemistry from Governors State University and a PhD in Analytical Chemistry from Northern Illinois University.
Pharma Marketing Network
JUNE 11, 2020
And when you look through who those Twitter followers are, it’s very heavily skewed towards industry, as is the website, we’ve also put some tools on our website to be able to look at who the visitors are, by company. Don Langsdorf (EHS): 141 different pharma companies from around the world. John Mack (PG): Yep.
The People's Pharmacy
MAY 8, 2023
Why, then, are FDA inspections abroad so infrequent and disappointing? FDA Inspections Suspended: During the COVID pandemic, the Food and Drug Administration suspended its inspections at most foreign pharmaceutical facilities. Even under the best of conditions, the FDA never inspects all foreign pharmaceutical plants annually.
PharmaShots
FEBRUARY 27, 2023
The speakers shared their views on the topic: Dr. Jagadeesh Babu Rangisetty- “COVID has taught us so many things and the pharmaceutical company has gone through a lot of challenges and at the same time opportunities. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. Letter to FDA, 06 July 2022.
Expert insights. Personalized for you.
133 
Let's personalize your content